Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Gastrointestinal 3Tumor-Agnostic 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Pancreatic Adenocarcinoma 1Colorectal Neoplasms 1Adenocarcinoma Pancreas 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
selicrelumab × Gastrointestinal × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Hoffmann-La Roche

Phase 1/2 Terminated
96 enrolled 24 charts
Gastrointestinal

Colorectal Neoplasms

NCT01456585 2018-08-27

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
10 enrolled
Gastrointestinal

Adenocarcinoma Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡